非酒精性脂肪肝哪家强？_老虎社区_美港股上老虎

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":808755886,"tweetId":"808755886","gmtCreate":1627612301945,"gmtModify":1627612301945,"author":{"id":3452938437060827,"authorId":3452938437060827,"authorIdStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"3dedd76b82b147d9878afe8793c4b4c8","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"下一个美股打新，会是大肉签吗？","type":3,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/discussion&rndata={\"themeId\":3dedd76b82b147d9878afe8793c4b4c8}&rnconfig={\"headerBarHidden\": true}","description":"药明康德、红杉资本等投资的天演药业和SaaS第一中概股容联云将在本月上市，2020年上市的中概股表现优异，这两家你看好吗？","image":"https://static.tigerbbs.com/109478ac79e7b1010aba611ffde0b0b2"}],"images":[],"coverImages":[],"title":"非酒精性脂肪肝哪家强？","extraTitle":"","html":"<html><head></head><body>投行BTIG认为<a target=\"_blank\" href=\"https://laohu8.com/S/ETNB\">$89Bio, Inc.(ETNB)$</a>&nbsp;和<a target=\"_blank\" href=\"https://laohu8.com/S/VKTX\">$Viking Therapeutics, Inc.(VKTX)$</a>&nbsp;列为非酒精性脂肪性肝炎（NASH）领域开发商的首选。分析师认为，这两家公司的主要候选者已经证明了NASH的“抗纤维化和抗脂肪变性”作用，NASH是一种以脂肪积聚和肝纤维化为特征的疾病。89bio和Viking的目标价格分别为60美元和20美元，这表明它们与收盘价相比，溢价分别约为302.4%和241.3%。89bio和Viking的市值大幅低于<a target=\"_blank\" href=\"https://laohu8.com/S/AKRO\">$Akero Therapeutics(AKRO)$</a>&nbsp;和<a target=\"_blank\" href=\"https://laohu8.com/S/MDGL\">$Madrigal Pharmaceuticals, Inc.(MDGL)$</a>&nbsp;，据分析师称，这两家公司是他们的“直接机械竞争对手”。但在过去六个月里，所有四家NASH治疗公司的表现都不如大盘。<a target=\"_blank\" href=\"https://laohu8.com/S/01672\">$歌礼制药-B(01672)$</a>&nbsp;</body></html>","htmlText":"<html><head></head><body>投行BTIG认为<a target=\"_blank\" href=\"https://laohu8.com/S/ETNB\">$89Bio, Inc.(ETNB)$</a>&nbsp;和<a target=\"_blank\" href=\"https://laohu8.com/S/VKTX\">$Viking Therapeutics, Inc.(VKTX)$</a>&nbsp;列为非酒精性脂肪性肝炎（NASH）领域开发商的首选。分析师认为，这两家公司的主要候选者已经证明了NASH的“抗纤维化和抗脂肪变性”作用，NASH是一种以脂肪积聚和肝纤维化为特征的疾病。89bio和Viking的目标价格分别为60美元和20美元，这表明它们与收盘价相比，溢价分别约为302.4%和241.3%。89bio和Viking的市值大幅低于<a target=\"_blank\" href=\"https://laohu8.com/S/AKRO\">$Akero Therapeutics(AKRO)$</a>&nbsp;和<a target=\"_blank\" href=\"https://laohu8.com/S/MDGL\">$Madrigal Pharmaceuticals, Inc.(MDGL)$</a>&nbsp;，据分析师称，这两家公司是他们的“直接机械竞争对手”。但在过去六个月里，所有四家NASH治疗公司的表现都不如大盘。<a target=\"_blank\" href=\"https://laohu8.com/S/01672\">$歌礼制药-B(01672)$</a>&nbsp;</body></html>","text":"投行BTIG认为$89Bio, Inc.(ETNB)$ 和$Viking Therapeutics, Inc.(VKTX)$ 列为非酒精性脂肪性肝炎（NASH）领域开发商的首选。 分析师认为，这两家公司的主要候选者已经证明了NASH的“抗纤维化和抗脂肪变性”作用，NASH是一种以脂肪积聚和肝纤维化为特征的疾病。 89bio和Viking的目标价格分别为60美元和20美元，这表明它们与收盘价相比，溢价分别约为302.4%和241.3%。 89bio和Viking的市值大幅低于$Akero Therapeutics(AKRO)$ 和$Madrigal Pharmaceuticals, Inc.(MDGL)$ ，据分析师称，这两家公司是他们的“直接机械竞争对手”。但在过去六个月里，所有四家NASH治疗公司的表现都不如大盘。 $歌礼制药-B(01672)$","highlighted":1,"essential":1,"paper":2,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/808755886","repostId":0,"isVote":1,"tweetType":1,"viewCount":12470,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["VKTX","AKRO","ETNB","01672","MDGL"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":533,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":5375541,"gmtCreate":1627612882272,"gmtModify":1627612882272,"authorId":3555971507886566,"author":{"id":3555971507886566,"authorId":3555971507886566,"name":"福泰阳光","avatar":"https://static.tigerbbs.com/f6c15bb67039a815e9402f32b3c3559f","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":808755886,"type":1,"supId":0,"prevId":0,"content":"好","text":"好","html":"好","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}

非酒精性脂肪肝哪家强？

评论（1）

热议股票